Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 16Neoplasms 6Colorectal Neoplasms 5Solid Tumors 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Noonan Syndrome 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Microsatellite Unstable Colorectal Cancer 1Lung Neoplasms 1Lung Diseases 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1

Interventions

Gemcitabine 35Cisplatin 21Capecitabine 17Oxaliplatin 16Leucovorin 11Fluorouracil 11pembrolizumab 8S 1 (combination) 8Nivolumab 6tremelimumab 5durvalumab 5Bevacizumab 5lenvatinib 4Irinotecan 4trametinib 3titanium silicide 3atezolizumab 3Radiofrequency Ablation 3zanidatamab 2vandetanib 2irinotecan sucrosofate 2derazantinib 2camrelizumab 2binimetinib 2apatinib 2Trastuzumab 2Tegafur 2Radiotherapy 2Panitumumab 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Biliary Tract Neoplasms × cobimetinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡